Novacea/Transcept Reverse Merger To Fund Intermezzo Sleep Aid Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
After Schering-Plough terminates Novacea Asentar deal, firm plans merger with Transcept in an all-stock transaction.
You may also be interested in...
With Reverse Merger Complete, Transcept Looks To Partner Intermezzo
Newly public specialty firm anticipates annual U.S. sales of $600 million for middle-of-night sleep aid.
With Reverse Merger Complete, Transcept Looks To Partner Intermezzo
Newly public specialty firm anticipates annual U.S. sales of $600 million for middle-of-night sleep aid.
Stuck In Reverse: Another Start-up Takes Reverse Merger Route To Public Markets
Deal results in unlikely combination of antbiotics maker Replidyne and device firm Cardiovascular Systems.